0A9G Stock Overview
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Mereo BioPharma Group plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.10 |
| 52 Week High | US$4.34 |
| 52 Week Low | US$0.94 |
| Beta | 0.80 |
| 1 Month Change | 15.89% |
| 3 Month Change | -16.55% |
| 1 Year Change | 165.41% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -1.59% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0A9G | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0.8% | 0.5% | 2.3% |
| 1Y | 165.4% | -22.3% | 5.5% |
Return vs Industry: 0A9G exceeded the UK Biotechs industry which returned -22% over the past year.
Return vs Market: 0A9G exceeded the UK Market which returned 5.8% over the past year.
Price Volatility
| 0A9G volatility | |
|---|---|
| 0A9G Average Weekly Movement | 8.2% |
| Biotechs Industry Average Movement | 7.7% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0A9G's share price has been volatile over the past 3 months.
Volatility Over Time: 0A9G's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 33 | Denise Scots-Knight | www.mereobiopharma.com |
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials.
Mereo BioPharma Group plc Fundamentals Summary
| 0A9G fundamental statistics | |
|---|---|
| Market cap | US$424.27m |
| Earnings (TTM) | -US$29.47m |
| Revenue (TTM) | US$10.00m |
41.6x
P/S Ratio-14.1x
P/E RatioIs 0A9G overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0A9G income statement (TTM) | |
|---|---|
| Revenue | US$10.00m |
| Cost of Revenue | US$2.57m |
| Gross Profit | US$7.43m |
| Other Expenses | US$36.89m |
| Earnings | -US$29.47m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.21 |
| Gross Margin | 74.26% |
| Net Profit Margin | -294.66% |
| Debt/Equity Ratio | 8.7% |
How did 0A9G perform over the long term?
See historical performance and comparison